A US-headquartered healthcare venture capital firm.
Headquartered in Cheyenne, Wyoming, OceansGled deploys concentrated cheques into US biotech, life sciences, MedTech and digital health companies — with the international reach to take them into Asia, the Gulf and Africa.
Where we invest in the United States
Therapeutics and platform biotech with human data or a defensible discovery engine, including AI-native drug discovery and precision oncology.
MedTech and diagnostics with a clear FDA pathway and reimbursement logic, and digital health companies whose economics improve with scale.
Life sciences tooling, biologics and antimicrobial resistance programmes where scientific advantage compounds into pricing power.
How we underwrite
Rigorous scientific, commercial and financial diligence across three continents. We invest after product readiness and initial validation, at Series A and beyond, with a minimum US$10 million cheque.
Portfolios are capped at 25 companies per fund so each position receives partner-level attention and reserved follow-on capital.
What US founders get beyond capital
Access to manufacturing and clinical capacity in India and Singapore, sovereign and family-office capital relationships in Abu Dhabi, and an operating bench across regulatory, commercial and senior hiring workstreams.
Frequently asked questions
- Is OceansGled a US-based healthcare venture capital firm?
- Yes. OceansGled LLC is headquartered in Cheyenne, Wyoming, with additional offices in Mumbai, Hyderabad, Chennai, Singapore and Abu Dhabi.
- What stage does OceansGled invest at?
- Series A and beyond, after product readiness and initial market validation, with a minimum cheque of US$10 million.
- How much capital does OceansGled manage?
- US$2.3 billion in cumulative AUM-equivalent, including US$950 million committed across Funds I–III plus co-investment vehicles, SPVs and managed advisory mandates.